GAMMA Investing LLC Purchases 9,422 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

GAMMA Investing LLC raised its position in Vaxcyte, Inc. (NASDAQ:PCVX) by 2,631.8% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 9,780 shares of the company’s stock after purchasing an additional 9,422 shares during the period. GAMMA Investing LLC’s holdings in Vaxcyte were worth $369,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the company. California State Teachers Retirement System increased its holdings in shares of Vaxcyte by 17.5% in the fourth quarter. California State Teachers Retirement System now owns 105,052 shares of the company’s stock worth $8,600,000 after acquiring an additional 15,616 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Vaxcyte in the 4th quarter valued at approximately $8,487,000. Forum Financial Management LP bought a new stake in Vaxcyte during the 4th quarter worth approximately $255,000. GF Fund Management CO. LTD. bought a new stake in Vaxcyte during the 4th quarter worth approximately $214,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Vaxcyte by 15.8% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 472,964 shares of the company’s stock worth $38,717,000 after buying an additional 64,690 shares during the period. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Trading Down 1.6%

Shares of PCVX stock opened at $32.87 on Friday. Vaxcyte, Inc. has a 1-year low of $27.66 and a 1-year high of $121.06. The stock has a market cap of $4.24 billion, a price-to-earnings ratio of -8.24 and a beta of 1.20. The stock has a 50-day moving average of $33.00 and a 200-day moving average of $61.20.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). During the same period last year, the company posted ($0.85) earnings per share. Sell-side analysts forecast that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Guggenheim reiterated a “buy” rating and set a $160.00 target price on shares of Vaxcyte in a report on Wednesday, March 12th. Needham & Company LLC reiterated a “buy” rating and set a $90.00 price objective on shares of Vaxcyte in a report on Tuesday, April 8th. Cantor Fitzgerald initiated coverage on Vaxcyte in a research report on Tuesday, April 22nd. They issued an “overweight” rating on the stock. Bank of America reduced their price target on Vaxcyte from $157.00 to $137.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. Finally, Evercore ISI raised shares of Vaxcyte to a “strong-buy” rating in a research note on Monday, March 31st. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $136.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.